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Purpose/Objective: Intra-Operative Radiation Therapy with 
low energy X-rays (XIORT) is largely used for breast cancer 
treatment with spherical applicators [1]. However, only a 
few centers are involved in superficial intraoperative 
radiotherapy [2] and little information is available about the 
dose distributions of the INTRABEAM® (Carl Zeiss) obtained 
with these dedicated applicators. This study proposes a fast 
and precise method to calculate dose distribution from 
Monte-Carlo phase space data in the case of flat and surface 
applicators. 
Materials and Methods: We developed a strategy to 
determine realistic Phase Space Files (PSF) that reproduces 
the experimental dose distributions. On one hand, 
monoenergetic PSF and corresponding depth-dose profiles 
(PDD) are generated only once with a full Monte-Carlo 
simulation using with the penEasy [3] code, one for each 
energy up to 50 keV (computing time of a few CPU-days). 
These simulations include a detailed geometry of the device 
which describes the general features of the experimental 
dose of standard flat and surface applicators. These 
monochromatic PSF are binned and parameterized in terms 
of the relevant variables to make them easy to manipulate. 
On the other hand, we take the energy spectrum as a fitting 
function which is optimized by means of a genetic algorithm 
[4] to describe the experimental PDD of any applicator. 
Finally, the binned precomputed monoenergetic phase space 
files and the fitted energy spectrum are combined to build 
the actual PSF optimized to describe the dose distribution of 
the considered applicator. From the final optimized phase 
space file, the dose is computed either by penEasy or by an 
in-house analytical algorithm which takes into account 
condensed history simulations of both photoelectric and 
Compton interactions for X-rays up to 50 keV. We compared 
the computed dose distributions with measurements first in 
water, then in homogeneous and heterogeneous media (lung, 
bone, air). 
Results: Building the fitted PSF only takes a few minutes in a 
single core (i7@2.5 GHz). Dose distributions computed with 
the proposed strategy from the optimized PSF are in good 
agreement with the measurements performed at the Institut 
Universitaire du Cancer (Toulouse, France) with the flat and 
surface applicators. 
Conclusions: The dose calculation process presented in this 
work is fast, flexible and optimized to simple experimental 
data. This method is being implemented into Radiance® 
(GMV SA, Spain), a powerful IORT Treatment Planning System 
[5], for all INTRABEAM (Carl Zeiss) applicators and can be 
used for a wide range of clinical indications.  
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Purpose/Objective: Breast Conservation Therapy (BCT) is the 
'gold standard' in early-stage breast cancer treatment. Many 
BCT patients also require a boost to the tumor bed in 
addition to 3 to 5 weeks of external beam radiation 
treatment (EBRT). There are several different technologies 
that can be used to boost the tumor bed. This study reviews 
these various technologies, compares the volumes irradiated, 
the dose distributions to the tumor bed, and the overall 
homogeneity of the treatment, as well as the dose which is 
delivered to critical structures. The advantages and 
disadvantages of each boost approach are discussed. 
Materials and Methods: To simplify comparison in this study, 
we selected patients to evaluate who had a maximum tumor 
dimension of 2 cm at the time of the surgery. We selected 
patients with left-breasted tumors to maximize the impact of 
each technique on treating critical structures. For patients 
treated totally with EBRT, we selected patients who started 
EBRT no later than 6 weeks post-surgery. Both 3 and 5 week 
EBRT treatment schedules were studied. The TPS system and 
home-made software evaluated the dose distributions of the 
combined EBRT boost and EBRT whole breast treatment. For 
patients treated with IORT, the dose map was added to the 
EBRT distribution with a suitable registration. Estimated RBE 
corrections were made for the 50 kV devices. The α/β model 
was used to convert IORT doses to normal fractionated EBRT 
doses. 
Results: Three (3) patients treated with each technique were 
studied and the results were averaged to obtain the final 
data for each technique. Dose to critical structures were 
compared for all techniques knowing that the driving factor 
for dose to critical structures is the EBRT dose, not the boost 
dose. In theory, IORT with electrons had the most uniform 
dose over the smallest boost volume of all boost techniques 
but several parameters can influence the boost volume (50 
KV applicator diameter, presence of a chest wall shield, 
etc...) 
Conclusions: There are significant variations in the volumes 
and dose homogeneity of the irradiated boost volumes 
depending on which boost technique is used, but this does 
not appear to significantly impact the overall physical dose 
distributions when the EBRT dose is added to the boost. BED 
variations are somehow greater. There are, however, 
significant differences in advantages in one technique over 
another, and these can result in both cosmetic and oncologic 
differences. 
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Purpose/Objective: Phase space files (PHSP) generation is a 
time consuming procedure and further the size of PHSP make 
them difficult to work with. We present a procedure to 
generate within a few minutes a PHSP which reproduces the 
experimental PDD, by optimizing the energy spectrum that 
fits the experimental dose data with a genetic algorithm [1], 
and using the information from a previously stored full 
database of monochromatic PHSP and percentage depth dose 
(PDD ) from a specific simulated accelerator. 
Materials and Methods: Mobile and linear accelerators used 
in intraoperative electron radiotherapy (IOERT), such as LIAC, 
NOVAC 7 and VARIAN 21EX, have been simulated in detail 
with penEasy [2]. A full set of monochromatic PHSP, covering 
the accelerators energy spectrum range from 1 MeV to 14 
MeV, have been calculated and stored (100 million histories, 
48 hours running time on a 8 cores high capacity cluster). 
Each PHSP is binned in the type of particle, energy, axial 
angle and radial position. PDD in water is obtained with these 
parameterized PHSP with DPM [3] and stored as well (1 hour 
computation time on a 8 cores high capacity cluster). These 
calculations, both the PHSP and the PDD simulations for the 
monochromatic PHSP, need to be done only once. After that, 
our procedure consists of two consecutive phases. In phase 
one, by means of a genetic algorithm, an optimized energy 
spectrum which weights the relative contributions of the 
monochromatic PDD that reproduces the experimental dose 
data is generated. In phase two, the previously simulated 
PHSP are weighted by this energy spectrum to obtain the 
resulting PHSP that fits the experimental measurements. 
These two phases have to be performed for each individual 
case, taking a few minutes computation time in a single core 
(i7@2.5 GHz) PC.  
Results: The genetic algorithm performs an accurate fitting 
of the monochromatic PDD to the experimental data. Dose 
calculated from the resulting weighted PHSP are in good 
agreement with the measurements for all the accelerators 
studied, not only the PDD but also transverse dose profiles 
(figure 1). Computation time is below 3 minutes in a single 
core PC. 
 
Figure 1. Transverse dose profiles in water 
 
Conclusions: Preliminary results show that the genetic 
algorithm-based method to determine PHSP from a 
experimental PDD in water reproduces dose distributions 
measured with different accelerators, accurately enough for 
IOERT planning. The method is flexible and fast, being able 
to obtain a PHSP for any accelerator within minutes. The 
genetic program and the PHSP weighting algorithms have 
been incorporated in Radiance® [4], a treatment planning 
system for intraoperative radiation therapy developed by the 
GMV company. 
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Purpose/Objective: Radiochromic films and MOSFETs have 
been used successfully for in vivo measurements during intra-
operative electron radiation therapy (IOERT) of breast 
cancer1. At our institution, surgery of locally advanced 
and/or recurrent rectal cancer is often complemented with 
IOERT. The aim of this study was to determine the actual 
dose delivered during IOERT of rectal cancer through in vivo 
measurements using Gafchromic EBT3 films. 
Materials and Methods: In vivo measurements were 
performed during IOERT treatments in 21 patients with 
advanced or recurrent rectal cancer. Treatments were 
performed with a Varian Clinac 2100 CD conventional linear 
accelerator, adapted for IOERT with a hard docking system of 
cylindrical applicators (5 to 10 cm diameter) and bevel angles 
of 0, 15, 30 and 45°.  
A small piece of Gafchromic film (1.5 x 1.5 cm2) wrapped in a 
sterile plastic envelope was placed by the radio-oncologist on 
the irradiation surface. Film position was documented by a 
photo taken before the irradiation. The films were digitized 
and the pixel values converted to dose using a previously 
obtained calibration curve. Results were analysed using 
ImageJ and Octave. 
Results: Good agreement between measured and expected 
values (diff. ≤ 7%) was obtained when irradiation surfaces 
were nearly flat and the film was positioned near the centre 
of the applicator (9 procedures).  
The other results were analysed individually, based on 
irradiation conditions, the surface geometry and the position 
of the film relative to the applicator. Concave or irregular 
irradiation surfaces are frequent in pelvic IOERT. Haematic 
fluid build up also occurs and bevelled applicators are 
frequently used. This leads to much more complicated 
irradiation geometries than for breast IOERT. Dose 
differences between 3% and 10% were observed within a 
single piece of Gafchromic film, depending on the irradiation 
conditions (Figure 1). This 2D dose distribution yields 
valuable information, and constitutes one advantages of 
using film instead of point detectors such as MOSFETs.  
 
Conclusions: These preliminary results confirm that in vivo 
dosimetry during pelvic IOERT is possible, and potentially 
